GP surgery closures hit ‘all-time-high’ last year
The closures are directly affecting smaller practices, with nine out of 10 practices that closed serving fewer than 5,000 patients.
3rd June 2019
Latest news
NICE recommendation for MSD’s Prevymis after re-evaluation
Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
3rd June 2019
Novartis hits targets in late-stage QMF149 asthma trial
The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control.
31st May 2019
BMJ study shows correlation between processed foods and CV disease
Cardiovascular disease is the main cause of death worldwide, representing one third of all deaths globally.
31st May 2019
NICE issues guidance revision for depression
The governing body has been urged to undergo a “full and proper revision” of its 2009 guideline on adult depression.
31st May 2019
Milestone achieved in J&J’s investigational HIV study
Johnson & Johnson has announced full enrolment in its proof-of-concept efficacy study of Imbokodo.
31st May 2019
NHS to launch new online type II diabetes support
The new online portal will offer people with type II diabetes evidence-based information and support.
30th May 2019
Record number of cancer drugs launched in 2018, says report
The IQVIA report also explores health system barriers hindering the realisation of the benefits of those therapies and drug candidates.
30th May 2019
FDA breakthrough therapy designation granted for Bayer’s Aliqopa
The decision was primarily based on follow-up data from the pivotal Phase II study CHRONOS-1.
30th May 2019
Univar’s Cufence leads latest CHMP decisions
The committee recommended four treatments including two generic medicines.
30th May 2019
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
29th May 2019
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
29th May 2019
Inpatients seen within target time falls to 68% in Scotland
Professor Derek Bell of the Royal College of Physicians of Edinburgh spoke out against the worsening figures.
29th May 2019
EMA gives trastuzumab biosimilar Marketing Authorisation Application
The drug is Prestige’s lead development candidate biosimilar to Roche’s Herceptin.
29th May 2019
FDA approval for Novartis’ Piqray
The FDA approval is based on a Phase III trial, SOLAR-1, in which the combination nearly doubled median progression free survival.
28th May 2019
